Levocetirizine: a review of its use in the management of allergic rhinitis and skin allergies.


:Levocetirizine (Xyzal) is a selective, potent, oral histamine H(1) receptor antagonist of the latest generation that is licensed for the symptomatic treatment of allergic rhinitis (including persistent allergic rhinitis [PER]) and chronic idiopathic urticaria (CIU). Large, well designed trials indicate that levocetirizine is effective and generally well tolerated in the treatment of allergic rhinitis and CIU. Its pharmacological profile offers many positive aspects: a rapid onset and long duration of antihistaminic effect; rapid absorption and high bioavailability; a low potential for drug interactions; a low volume of distribution; and a lack of effect on cognition, psychomotor function and the cardiovascular system. Allergen challenge chamber studies suggest that levocetirizine has better efficacy than desloratadine, loratadine or fexofenadine. Well controlled, long-term studies with other later-generation H(1) receptor antagonists are required to fully define its clinical profile relative to other agents in this class. Overall, levocetirizine is a valuable addition to the oral H(1) receptor antagonists available for the treatment of allergic rhinitis and as first-line therapy in patients with CIU.






Hair PI,Scott LJ




Has Abstract


2006-01-01 00:00:00
















  • Sickle cell disease in children.

    abstract::Early identification of infants with sickle cell disease (SCD) by newborn screening, now universal in all 50 states in the US, has improved survival, mainly by preventing overwhelming sepsis with the early use of prophylactic penicillin. Routine transcranial Doppler screening with the institution of chronic transfusio...


    pub_type: 杂志文章,评审


    authors: Meier ER,Miller JL

    更新日期:2012-05-07 00:00:00

  • Cenobamate: First Approval.

    abstract::Cenobamate (XCOPRI®) is an oral, small molecule neurotherapeutic azole compound that is being developed by SK Life Science Inc. and Arvelle Therapeutics for the treatment of epilepsy. Based on results of two pivotal phase 2 trials, cenobamate was recently approved in the USA for use in the treatment of partial-onset s...


    pub_type: 杂志文章,评审


    authors: Keam SJ

    更新日期:2020-01-01 00:00:00

  • Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome.

    abstract::Several large-scale clinical trials have assessed the efficacy of atorvastatin in the primary and secondary prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome. In primary prevention, CARDS (Collaborative Atorvastatin Diabetes Study) showed that atorvastatin 10 mg/day (vs p...


    pub_type: 杂志文章,评审


    authors: Arca M

    更新日期:2007-01-01 00:00:00

  • Brodalumab: First Global Approval.

    abstract::Brodalumab (Lumicef(®)) is a human monoclonal immunoglobulin G antibody that is being developed by Kyowa Hakko Kirin in Japan, where it has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. Brodalumab binds with high affinity to interleukin (IL)-...


    pub_type: 杂志文章


    authors: Greig SL

    更新日期:2016-09-01 00:00:00

  • Inflammatory bowel disease management. Some thoughts on future drug developments.

    abstract::This article is intended to stimulate thought and focus on those areas where we feel advances in drug therapy for inflammatory bowel disease may occur. It is not an extensive review of current practice, although this is considered where it is thought to be pertinent to future developments. There are several excellent ...


    pub_type: 杂志文章,评审


    authors: Rhodes J,Thomas G,Evans BK

    更新日期:1997-02-01 00:00:00

  • Levonorgestrel subdermal implants. A review of contraceptive efficacy and acceptability.

    abstract:UNLABELLED:Levonorgestrel 6-capsule subdermal implants (Norplant) are an effective form of reversible contraception. When implanted under the skin of the upper arm, they release drug into the circulation at a relatively constant rate over 5 years. Generally, the cumulative pregnancy rate at the end of 5 years' levonorg...


    pub_type: 杂志文章,评审


    authors: Coukell AJ,Balfour JA

    更新日期:1998-06-01 00:00:00

  • Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial.

    abstract:BACKGROUND:The combination of an inhaled corticosteroid (ICS) and a long-acting bronchodilator is recommended in the treatment of patients with chronic obstructive pulmonary disease (COPD) who have frequent exacerbations. Budesonide/formoterol dry powder inhaler (DPI) has demonstrated efficacy and tolerability in patie...


    pub_type: 杂志文章,多中心研究,随机对照试验


    authors: Tashkin DP,Rennard SI,Martin P,Ramachandran S,Martin UJ,Silkoff PE,Goldman M

    更新日期:2008-01-01 00:00:00

  • Selection of vasodilator drugs for patients with severe chronic heart failure: an approach based on a new classification.

    abstract::Although vasodilator drugs are of proven worth in the management of patients with severe heart failure, a useful system of classification of vasodilator drugs has not yet been devised. The traditional system of classification based on the dominant arterial and/or venous sites of action as determined by limb plethysmog...


    pub_type: 杂志文章,评审


    authors: Packer M

    更新日期:1982-07-01 00:00:00

  • Lixisenatide: first global approval.

    abstract::The selective once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist lixisenatide (Lyxumia(®)) is under development with Sanofi for the treatment of type 2 diabetes mellitus. Lixisenatide belongs to a class of GLP-1 compounds designed to mimic the endogenous hormone GLP-1. Native GLP-1 stimulates insulin...


    pub_type: 杂志文章,评审


    authors: Elkinson S,Keating GM

    更新日期:2013-03-01 00:00:00

  • Tuberculosis and HIV co-infection: screening and treatment strategies.

    abstract::Globally, tuberculosis (TB) and HIV interact in deadly synergy. The high burden of TB among HIV-infected individuals underlies the importance of TB diagnosis, treatment and prevention for clinicians involved in HIV care. Despite expanding access to antiretroviral therapy (ART) to treat HIV infection in resource-limite...


    pub_type: 杂志文章,评审


    authors: Venkatesh KK,Swaminathan S,Andrews JR,Mayer KH

    更新日期:2011-06-18 00:00:00

  • [Clinical experience with nifedipine in the treatment of angina pectoris in Japan].

    abstract::Developed by Bayer in Germany, nifedipine was shown to be effective in the treatment of patients with angina pectoris by Japanese investigators. Professor Kimura first reported the efficacy of nifedipine in patients with angina pectoris and those findings have been replicated in numerous trials conducted since then. C...


    pub_type: 杂志文章,评审


    authors: Hosoda S

    更新日期:2006-01-01 00:00:00

  • Peramivir: A Review in Uncomplicated Influenza.

    abstract::Intravenous peramivir (Alpivab™; Rapivab®; Rapiacta®; PeramiFlu®), the most recent globally approved inhibitor of influenza neuraminidase, is indicated for the treatment of uncomplicated influenza in adults and children from the age of 2 years. This article, written from an EU perspective, reviews the clinical use of ...


    pub_type: 杂志文章,评审


    authors: Scott LJ

    更新日期:2018-09-01 00:00:00

  • Anidulafungin, a new echinocandin: in vitro activity.

    abstract::Anidulafungin is an antifungal drug belonging to the echinocandin class with a potent in vitro fungicidal activity against a wide range of Candida species, including C. glabrata and C. krusei. Anidulafungin is also active in vitro against moulds belonging to the genus Aspergillus and some dematiaceous genera. Furtherm...


    pub_type: 杂志文章,评审


    authors: Morace G,Borghi E,Iatta R,Montagna MT

    更新日期:2009-01-01 00:00:00

  • Practical aspects of the use of amiodarone.

    abstract::Amiodarone is a class III antiarrhythmic drug with sympatholytic properties, which prolongs the refractory period of all cardiac tissues, depresses sinus node automaticity and atrioventricular nodal conduction. It is active on all cardiac arrhythmias, its use being limited by the risk of side effects, mainly extracard...


    pub_type: 杂志文章,评审


    authors: Puech P

    更新日期:1991-01-01 00:00:00

  • Second-generation antihistamines: a comparative review.

    abstract::Second-generation histamine H1 receptor antagonists (antihistamines) have been developed to reduce or eliminate the sedation and anticholinergic adverse effects that occur with older H1 receptor antagonists. This article evaluates second-generation antihistamines, including acrivastine, astemizole, azelastine, cetiriz...


    pub_type: 杂志文章,meta分析


    authors: Slater JW,Zechnich AD,Haxby DG

    更新日期:1999-01-01 00:00:00

  • Filgrastim. A review of its pharmacological properties and therapeutic efficacy in neutropenia.

    abstract::Filgrastim, a recombinant human granulocyte colony-stimulating factor (G-CSF), has identical biological activity to that of endogenous human G-CSF, but differs in that it contains an N-terminal methionine residue and is not glycosylated. It principally stimulates activation, proliferation and differentiation of neutro...


    pub_type: 杂志文章,评审


    authors: Frampton JE,Lee CR,Faulds D

    更新日期:1994-11-01 00:00:00

  • Zimelidine: a review of its pharmacological properties and therapeutic efficacy in depressive illness.

    abstract::Zimelidine is a new antidepressant, which is structurally unrelated to the tricyclic and tetracyclic antidepressants. The pharmacological profile of zimelidine is different to that of other antidepressants in that it appears to owe the major part of its activity to the inhibition of serotonin uptake within the central...


    pub_type: 杂志文章,评审


    authors: Heel RC,Morley PA,Brogden RN,Carmine AA,Speight TM,Avery GS

    更新日期:1982-09-01 00:00:00

  • Management of insomnia in patients with chronic obstructive pulmonary disease.

    abstract::Chronic obstructive pulmonary disease (COPD) is a common medical disorder, which causes considerable morbidity and mortality. Given the chronic and symptomatic nature of the disease, the patient is often seen in the physician's office with complaints of dyspnea. However, more than 50% of COPD patients also have sleep ...


    pub_type: 杂志文章,评审


    authors: George CF,Bayliff CD

    更新日期:2003-01-01 00:00:00

  • Somatropin (Zorbtive): in short bowel syndrome.

    abstract::A somatropin preparation (Zorbtive) produced by recombinant DNA technology has been evaluated in patients with short bowel syndrome. Somatropin is thought to enhance intestinal adaptation in this condition through direct or indirect effects on the intestine. In a randomised, double-blind study in patients with short b...


    pub_type: 杂志文章,评审


    authors: Keating GM,Wellington K

    更新日期:2004-01-01 00:00:00

  • Pancreatic cancer: a review of emerging therapies.

    abstract::The incidence of adenocarcinoma of the pancreas has risen steadily over the past 4 decades. Since pancreatic cancer is diagnosed at an advanced stage, and because of the lack of effective therapies, the prognosis of such patients is extremely poor. Despite advances in our understanding of the molecular biology of panc...


    pub_type: 杂志文章,评审


    authors: Rosenberg L

    更新日期:2000-05-01 00:00:00

  • Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis.

    abstract::Echinocandins are a new class of antifungal agents with a novel mechanism of action (interference with fungal cell wall synthesis). Caspofungin (Cancidas), Caspofungin MSD) is the first echinocandin to be approved and is administered intravenously. Caspofungin 50 mg/day had similar efficacy to intravenous fluconazole ...


    pub_type: 杂志文章,评审


    authors: Keating G,Figgitt D

    更新日期:2003-01-01 00:00:00

  • Sacituzumab Govitecan: First Approval.

    abstract::Sacituzumab govitecan (sacituzumab govitecan-hziy; Trodelvy™) is a Trop-2-directed antibody conjugated to a topoisomerase I inhibitor (SN-38) that is being developed by Immunomedics for the treatment of solid tumours, including breast cancer. In April 2020, sacituzumab govitecan received accelerated approval in the US...


    pub_type: 杂志文章,评审


    authors: Syed YY

    更新日期:2020-07-01 00:00:00

  • Dual inhibitory action of nedocromil sodium on antigen-induced inflammation.

    abstract::In human lung tissue in vitro, nedocromil sodium inhibited the release of histamine and leukotrienes induced by anti-IgE, as well as the contraction of isolated bronchi which followed this challenge. In the hamster cheek pouch in vivo, nedocromil sodium inhibited the inflammatory response induced by challenge with eit...


    pub_type: 杂志文章


    authors: Dahlén SE,Björck T,Kumlin M,Sydbom A,Raud J,Palmertz U,Franzén L,Grönneberg R,Hedqvist P

    更新日期:1989-01-01 00:00:00

  • Damoctocog Alfa Pegol: A Review in Haemophilia A.

    abstract::Damoctocog alfa pegol (Jivi®) is approved in the USA, EU, Japan and Canada for the treatment and prophylaxis of previously treated patients aged ≥ 12 years with haemophilia A. Formulated with a 60 kDa polyethylene glycol (PEG) moiety, damoctocog alfa pegol is an intravenously (IV) administered recombinant factor VIII ...


    pub_type: 杂志文章,评审


    authors: Paik J,Deeks ED

    更新日期:2019-07-01 00:00:00

  • Isradipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease.

    abstract::Isradipine, a dihydropyridine derivative, inhibits the inward calcium flux through 'slow' channels of cardiac and vascular tissue, thereby eliciting potent coronary, cerebral and peripheral vasodilatation. In comparison with other calcium channel blockers the drug offers the advantages of minimal cardiodepressant acti...


    pub_type: 杂志文章,评审


    authors: Fitton A,Benfield P

    更新日期:1990-07-01 00:00:00

  • Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris.

    abstract::Bisoprolol is a beta 1-adrenoceptor antagonist with no partial agonist (intrinsic sympathomimetic) activity or membrane stabilising (local anaesthetic) activity. The oral bioavailability of bisoprolol is high (90%) and the drug has a long elimination half-life which allows once-daily administration; in addition, it is...


    pub_type: 杂志文章,评审


    authors: Lancaster SG,Sorkin EM

    更新日期:1988-09-01 00:00:00

  • Concentration of sulbactam and ampicillin in serum and the myometrium.

    abstract::Sulbactam 1g and ampicillin 2g were administered intravenously to 12 patients, and concentrations of the drugs were determined in the serum and myometrium for up to 120 minutes after infusion. The ratio of sulbactam to ampicillin was about 1:2 in the serum and myometrium. Both drugs penetrated well into the myometrium...


    pub_type: 杂志文章


    authors: Schwiersch U,Lang N,Wildfeuer DA

    更新日期:1986-01-01 00:00:00

  • Antidiabetic drugs present and future: will improving insulin resistance benefit cardiovascular risk in type 2 diabetes mellitus?

    abstract::Results from the United Kingdom Prospective Diabetes Study showed that intensive treatment of type 2 (non-insulin-dependent) diabetes mellitus, with sulphonylureas or insulin, significantly reduced microvascular complications but did not have a significant effect on macrovascular complications after 10 years. Insulin ...


    pub_type: 杂志文章,评审


    authors: Campbell IW

    更新日期:2000-11-01 00:00:00

  • Selectivity of Janus Kinase Inhibitors in Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases: Is Expectation the Root of All Headache?

    abstract::Janus kinase (JAK) is a signal transducer and activator of a protein transcription system that transduces signals from cell surface cytokine and growth factor receptors to the nucleus. Recently developed JAK inhibitors (JAKinibs) inhibit JAKs non-selectively or selectively and down-regulate the effects of correspondin...


    pub_type: 杂志文章,评审


    authors: Harigai M,Honda S

    更新日期:2020-08-01 00:00:00

  • Trifluridine: a review of its antiviral activity and therapeutic use in the topical treatment of viral eye infections.

    abstract::Trifluridine (trifluorothymidine) is an antiviral agent for topical use in the eye, and is structurally related to idoxuridine. In vitro studies have shown that it effectively inhibits the replication of herpes simplex virus type 1, which causes primary keratoconjunctivitis and recurrent epithelial keratitis in man. I...


    pub_type: 杂志文章,评审


    authors: Carmine AA,Brogden RN,Heel RC,Speight TM,Avery GS

    更新日期:1982-05-01 00:00:00